Alector to License AL050 to Genentech for $100 Million Upfront

The Tip Desk · October 26, 2026 · 2 min read

The neurodegeneration biotech grants Genentech worldwide rights to its brain-penetrant GCase enzyme replacement therapy while keeping ownership of its ABC platform.

Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on neurodegeneration, granted Genentech exclusive worldwide rights to develop and commercialize AL050, its brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy, in a deal that includes a $100 million upfront payment, potential milestone payments of up to $1.17 billion, and tiered royalties on net sales.

Alector said it retains ownership of its Alector Brain Carrier (ABC) platform and full rights to apply that technology across its wholly owned pipeline. The structure lets the company bank near-term cash while keeping the delivery platform that underpins several other ABC-enabled programs.

AL050 is designed to address enzyme delivery to the brain, pairing an engineered GCase with improved activity and stability and a silenced effector function with tunable ABC technology. Preclinical studies to date have shown increased GCase activity in rodents and non-human primates and reduced toxic substrate accumulation in a rodent GBA disease model, with no apparent hematologic findings. The company had been targeting an IND submission for AL050 in 2027.

“Deficient GCase activity is increasingly recognized as a contributor to Parkinson’s Disease, and there is still no approved therapy that addresses the underlying enzyme deficiency,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.

The partnership shifts development of that Parkinson’s candidate to Genentech while Alector continues to advance other ABC-enabled programs, including AL137, an ABC-enabled anti-amyloid beta antibody for Alzheimer’s disease, and ABC-enabled siRNA programs targeting tau, alpha-synuclein, and NLRP3. Alector had previously said it is targeting IND submissions for AL137 in 2026 and for AL050 in 2027. With AL050 now licensed out, the company said it retains the ABC platform and full rights to apply it across its wholly owned pipeline.